GlassScriptPhysician profile
Dwight J Schroeder
NPI 1528047081
$12,571.64
in general payments reported to CMS, 2019-2025
33 companies · $2,589 in 2025
The $2,589 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,031 · 2020: $1,111 · 2021: $1,818 · 2022: $1,642 · 2023: $1,996 · 2024: $2,384 · 2025: $2,589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,969.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,614.20 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $1,345.65 | 2019-2025 | Aristada, Lybalvi |
| Abbvie INC. | $1,141.81 | 2021-2025 | Vraylar |
| Neurocrine Biosciences, INC. | $1,121.09 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,001.38 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $836.98 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Lundbeck LLC | $772.28 | 2019-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $678.83 | 2022-2025 | Qelbree, Qelbree |
| Allergan, INC. | $460.22 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $447.20 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $446.72 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Ironshore Pharmaceuticals INC. | $367.34 | 2019-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $331.34 | 2019-2022 | |
| Corium, LLC | $264.87 | 2022-2024 | Azstarys |
| Vanda Pharmaceuticals INC. | $234.71 | 2019-2025 | Fanapt |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $232.92 | 2023-2025 | Auvelity |
| Almatica Pharma LLC | $187.37 | 2021-2025 | Loreev Xr |
| E.R. Squibb & Sons, L.L.C. | $182.38 | 2024-2025 | Cobenfy |
| Jazz Pharmaceuticals INC. | $181.57 | 2019-2022 | |
| Harmony Biosciences LLC | $132.25 | 2022-2025 | Wakix |
| Merck Sharp & Dohme LLC | $82.03 | 2023 | Belsomra |
| Bausch Health US, LLC | $76.36 | 2019-2022 | |
| Indivior INC. | $75.79 | 2022-2023 | Perseris |
| Vertical Pharmaceuticals, LLC | $74.10 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $58.99 | 2025 | Jornay Pm |
| Shire North American Group INC | $52.19 | 2019 | |
| Idorsia Pharmaceuticals US INC | $41.00 | 2022-2023 | Quviviq |
| Avanir Pharmaceuticals, INC. | $40.29 | 2022 | |
| Alfasigma USA, INC. | $24.43 | 2022 | |
| Eisai INC. | $23.52 | 2020-2022 | |
| Tris Pharma INC | $15.71 | 2023 | Dyanavel Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $13.65 | 2022 | |
| Neuronetics, INC. | $12.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dwight Schroeder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.